1. Home
  2. EHI vs RCEL Comparison

EHI vs RCEL Comparison

Compare EHI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Global High Income Fund Inc

EHI

Western Asset Global High Income Fund Inc

HOLD

Current Price

$6.09

Market Cap

183.9M

Sector

Finance

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$4.23

Market Cap

171.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHI
RCEL
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
226
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.9M
171.5M
IPO Year
2003
N/A

Fundamental Metrics

Financial Performance
Metric
EHI
RCEL
Price
$6.09
$4.23
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.88
AVG Volume (30 Days)
77.3K
209.0K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.17
Revenue Next Year
N/A
$49.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.80
$3.22
52 Week High
$6.70
$9.85

Technical Indicators

Market Signals
Indicator
EHI
RCEL
Relative Strength Index (RSI) 45.55 45.03
Support Level $5.80 $3.98
Resistance Level $6.46 $4.57
Average True Range (ATR) 0.06 0.29
MACD -0.00 -0.06
Stochastic Oscillator 23.08 10.08

Price Performance

Historical Comparison
EHI
RCEL

About EHI Western Asset Global High Income Fund Inc

Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Financials, Energy, Communication energy, Industrials, materials, and others.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: